Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma

Recruiting

You are on the General Public view
  • Source

    -
    Public Title Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
    Acronym Sorry, not currently available
    Source of Record URL http://clinicaltrials.gov/show/NCT00450593
  • Trial

    -
    Health Condition(s) or Problem Hereditary Multiple Melanoma; Melanoma (Skin)
    Lay Summary RATIONALE: Identifying gene mutations and other risk factors in patients with melanoma and in families with a history of hereditary melanoma may help doctors identify persons at risk for melanoma and other types of cancer. It may also help the study of cancer in the future. PURPOSE: This clinical trial is studying gene mutations in patients with melanoma and in families with a history of hereditary melanoma. (from ClinicalTrials.gov)
    Who can enter the trial DISEASE CHARACTERISTICS: - Meets one of the following criteria: - Prior multiple primary melanomas - Histological samples available - Family history of melanoma, with melanoma in two first-degree relatives (e.g., cases of melanoma in both a mother and son or in two brothers but not in two cousins) - Family history of melanoma, where three or more individuals (of any relationship) have had melanoma PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified
    Who cannot enter the trial DISEASE CHARACTERISTICS: - Meets one of the following criteria: - Prior multiple primary melanomas - Histological samples available - Family history of melanoma, with melanoma in two first-degree relatives (e.g., cases of melanoma in both a mother and son or in two brothers but not in two cousins) - Family history of melanoma, where three or more individuals (of any relationship) have had melanoma PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified
    What will happen Genetic; gene expression analysis; Genetic; microarray analysis; Genetic; molecular genetic technique; Genetic; mutation analysis; Other; laboratory biomarker analysis; Procedure; mutation carrier screening; Procedure; study of high risk factors
    Primary aim Predictive significance of melanoma susceptibility gene (MSG) mutations in the CDKN2A gene; Susceptibility to other types of cancer as a feature of MSG mutations; Risk of other types of cancers in mutation carriers; Environmental exposures, in particular sun exposure, that modify risk of melanoma in MSG mutation carriers
    Secondary Aim Sorry, not currently available
    Participant Information Sheet Sorry, not currently available
    Website Sorry, not currently available
    Recruitment Status Recruiting
    Nation England
    Location Leeds
  • Contact

    -
    Contact for Public Queries Julia Newton Bishop, MD Study Chair Leeds Cancer Centre at St. James's University Hospital
    Contact for Scientific Queries Sorry, not currently available
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.